- Ongoing, recruitingPhase II and Phase III (Integrated)
A randomized, open label, multicenter phase II/III trial of sacituzumab govitecan compared to standard of care in metastatic, refractory colorectal cancer patients (TROPHIT1)
This study is looking at a new treatment called sacituzumab govitecan for bowel cancer that has spread and isn't responding to other treatments. It compares this new drug to standard treatments to see which works best at stopping the cancer from growing.
For: Metastatic Colorectal cancer (mCRC)Germany - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 study of MK-4280A (coformulated favezelimab [MK-4280] plus pembrolizumab [MK-3475]) Versus Standard of Care in Previously Treated Metastatic PD-L1 positive Colorectal Cancer (KEYFORM-007)
This study looks at a new drug combination, MK-4280A, for bowel cancer that has spread and has been treated before. It compares this new treatment to standard care to see if it helps people live longer and improves their quality of life.
For: Colorectal CancerItaly · Norway · France - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase 1b/2, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients with Metastatic Colorectal Cancer
This study is looking at new ways to treat advanced bowel cancer (colorectal cancer that has spread). It combines existing treatments with new drugs to see if they work better together. The aim is to find safer and more effective options for patients.
For: Metastatic colorectal cancerFrance · Italy · Spain - Active not recruitingPHASE3
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer
This study compares two treatments, XL092 (plus atezolizumab) and regorafenib, for advanced bowel cancer that has spread. It's for people whose cancer hasn't responded well to previous common treatments. We want to see which treatment works better to control the cancer.
For: Colorectal CancerUnited States · Australia · Belgium - RecruitingPHASE1, PHASE2
FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
This study, FaR-RMS, is for children and adults with a type of cancer called rhabdomyosarcoma. It's looking for better ways to treat both newly diagnosed and returning cancer, using different combinations of medicines and radiotherapy.
For: RhabdomyosarcomaAustralia · Austria · Belgium - AuthorisedTherapeutic exploratory (Phase II)
Monocentric Pilot Trial evaluating the safety and efficacy of Regorafenib in Arterio-Venous Malformations that are refractory to standard care
This study is testing a medicine called regorafenib for a rare condition called Arterio-Venous Malformations (AVMs). It's for people whose AVMs haven't improved with usual treatments. We want to see if the medicine can make people feel better, reduce their pain, and shrink their AVMs over 12 months.
For: Arterio-Venous MalformationsBelgium